WebApr 6, 2024 · Get a technical analysis of T2 Biosystems (TTOO) with the latest MACD of -0.10 and RSI of 23.17. Stay up-to-date on market trends with our expert analysis. Top Stocks. Top Analyst Stocks Top Smart Score Stocks Top Insiders Stocks. Popular. Stock Screener Top Online Growth Stocks Trending Stocks Penny Stock Screener. WebApr 6, 2024 · T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The Company is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, …
TTOO - T2 Biosystems Inc Stock Price Quote - NASDAQ
Web1 day ago · Analyst Forecast. According to 8 analysts, the average rating for TTOO stock is "Sell." The 12-month stock price forecast is $0.59, which is an increase of 44.96% from the latest price. Detailed statistics for T2 Biosystems, Inc. (TTOO) stock, including valuation … WebApr 12, 2024 · 4 Wall Street research analysts have issued 1 year price objectives for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $2.50. On … theos tauberbischofsheim
Mizuho warned by regulator for setting IPO prices too low
WebTTOO T2 Biosystems Inc (NASDAQ:TTOO) displayed relative strength on Friday closing above its 50-day exponential moving average for the first time since March. If the stock price remains above this level, investors will assess this development as a sign of strength. From the technical analysis perspective T2 Biosystems Inc (NASDAQ:TTOO) displayed relative … WebApr 13, 2024 · Microvast Competitors. $672.06 million. $9.15 million. 4.26. Microvast’s rivals have higher revenue and earnings than Microvast. Microvast is trading at a lower price-to-earnings ratio than its ... WebApr 12, 2024 · T2 Biosystems (NASDAQ:TTOO – Get Rating) and KORU Medical Systems (NASDAQ:KRMD – Get Rating) are both small-cap medical companies, but which is the superior investment?We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, … shubham maheshwari investec